Dudediligence.

Zymeworks Inc

ZYMENASDAQ · Pharmaceutical Preparations
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$20.1M

14 notices · 825,287 sh

Oct 2025 to Oct 2026

Reported ·

$4,673,716

10 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

None of the 10 reported sales carry the 10b5-1 box. Together they are 0.26% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-03-06: Jeffrey T L Smith, Form 1442026-02-17: Leone D Patterson, Form 1442026-02-13: Leone D Patterson, Form 1442026-01-12: Leone D Patterson, Form 1442026-01-12: Jeffrey T L Smith, Form 1442026-01-12: Paul Andrew Moore, Form 1442026-01-12: Mark Hollywood, Form 1442026-01-12: Kenneth Galbraith, Form 1442026-01-05: Smith Jeffrey T L, Form 1442026-01-05: Kenneth Galbraith, Form 1442026-01-05: Paul Andrew Moore, Form 1442025-12-22: Galbraith, Kenneth, Form 1442025-11-24: Derek John Michael Miller, Form 1442025-11-21: Neil Gallagher, Form 1442025-12-22: Galbraith Kenneth, sold2026-01-05: Moore Paul Andrew, sold2026-01-05: Galbraith Kenneth, sold2026-01-05: Smith Jeffrey T L, sold2026-01-12: Galbraith Kenneth, sold2026-01-12: Moore Paul Andrew, sold2026-01-12: Smith Jeffrey T L, sold2026-01-12: Hollywood Mark, sold
under a no plan named▼ salesize is dollars

Form 144 notices, newest first

2026-03-06Jeffrey T L Smith, EVP & Chief Medical Officer$6,133,858
247,333 shno plan dateno Form 4 on file144 ↗
2026-02-17Leone D Patterson, EVP, Chief Bus & Fin Officer$715,087
31,641 shno plan dateno Form 4 on file144 ↗
2026-02-13Leone D Patterson, EVP, Chief Bus & Fin Officer$2,978,457
128,548 shno plan dateno Form 4 on file144 ↗
2026-01-12Leone D Patterson, EVP, Chief Bus & Fin Officer$158,297
6,832 shno plan dateno Form 4 on file144 ↗
2026-01-12Jeffrey T L Smith, EVP & Chief Medical Officer$215,713
9,310 shno plan date144 ↗
Form 4, 2026-01-12: sold 9,310 at $22.67 Form 4 ↗
2026-01-12Paul Andrew Moore, Chief Scientific Officer$221,505
9,560 shno plan date144 ↗
Form 4, 2026-01-12: sold 9,560 at $22.67 Form 4 ↗
2026-01-12Mark Hollywood, EVP & Chief Operating Officer$141,800
6,120 shno plan date144 ↗
Form 4, 2026-01-13: sold 6,120 at $22.67 Form 4 ↗
2026-01-12Kenneth Galbraith, Chair & CEO$704,924
30,424 shno plan date144 ↗
Form 4, 2026-01-12: sold 30,424 at $22.67 Form 4 ↗
2026-01-05Smith Jeffrey T L, EVP & Chief Medical Officer$280,522
10,538 shno plan date144 ↗
Form 4, 2026-01-05: sold 10,538 at $25.10 Form 4 ↗
2026-01-05Kenneth Galbraith, Chair & CEO$1,446,611
54,343 shno plan date144 ↗
Form 4, 2026-01-05: sold 54,343 at $25.10 Form 4 ↗
2026-01-05Paul Andrew Moore, Chief Scientific Officer$535,328
20,110 shno plan date144 ↗
Form 4, 2026-01-05: sold 20,110 at $25.10 Form 4 ↗
2025-12-22Galbraith, Kenneth, Chair & CEO$1,294,187
47,528 shno plan date144 ↗
Form 4, 2025-12-22: sold 47,528 at $27.02 Form 4 ↗
2025-11-24Derek John Michael Miller, Former Director$2,810,760
118,000 shno plan dateno Form 4 on file144 ↗
2025-11-21Neil Gallagher, Former Director$2,501,100
105,000 shno plan dateno Form 4 on file144 ↗